id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-290200-csmisulw	Friedlaender, Alex	Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic	2020-05-12		.txt	text/plain	4022	189	50	Immune checkpoint inhibitors (ICPIs) have revolutionized the management and prognosis of fit patients with advanced non-small cell lung cancer (NSCLC). In the OAK trial, assessing the efficacy of the anti-PD-L1 antibody, atezolizumab, until progression or unacceptable toxicity in previously treated advanced NSCLC, regardless of PD-L1 expression, patients, 28% of those in the experimental arm demonstrated long-term survival, defined as greater or equal to 24 months (10). In the Checkmate 153 trial, continuous nivolumab treatment resulted in grade 3 or higher immune-related adverse events in 8% of patients, compared to 4% in the 1-year fixed duration cohort, but very few new safety events took place after the first year of therapy (8) . CheckMate 153: randomized results of continuous vs 1-year fixed-duration nivolumab in patients with advanced non-small-cell lung cancer Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study	./cache/cord-290200-csmisulw.txt	./txt/cord-290200-csmisulw.txt